The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Sanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming the first direct rival to Johnson & Johnson’s big-selling Darzalex.

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...

Adding isatuximab, an anti-CD38 monoclonal antibody, to bortezomib, lenalidomide, and dexamethasone (VRd) may improve outcomes in transplant-ineligible patients with multiple myeloma. New research ...

In addition, two new chemoimmunotherapy drugs — daratumumab and isatuximab — that specifically target multiple myeloma were ...

DelveInsight’s Refractory Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop ...

Examples are Darzalex (daratumumab) and Sarclisa (isatuximab). If you are eligible, you may receive a stem cell transplant ...

RIO DE JANEIRO — A quadruplet induction regimen of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in the treatment of newly diagnosed multiple myeloma (MM) shows a notably ...

In September, commenced patient dosing to investigate evorpacept plus SARCLISA® (isatuximab-irfc) and dexamethasone in ...

Binod Dhakal, MD, MS, discusses how the efficacy results observed with ciltacabtagene autoleucel in the CARTITUDE-4 trial compare with other therapies that are used for the treatment of ...

Total hip replacement is routinely recommended for severe hip osteoarthritis, but data from randomized trials are lacking regarding comparison of the effectiveness of this procedure with that of ...

November 4, 2024 • How did life start on Earth? The answer is a big scientific mystery scientists are actively investigating. After talking with many scientists, host Regina G. Barber found that ...